The detection of circulating plasma cells may improve the Revised International Staging System (R‐ISS) risk stratification of patients with newly diagnosed multiple myeloma
- 1 April 2021
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 193 (3) , 542-550
Abstract
Summary: The Revised International Staging System (R‐ISS) stratifies patients affected by Multiple Myeloma (MM) into three distinct risk groups: R‐ISS I [ISS Stage I, Standard‐Risk cytogenetics and normal Lactase DeHydrogenase (LDH)], R‐ISS III (ISS stage III and either high‐risk cytogenetics or high LDH) and R‐ISS II (any other characteristics). With the aim to verify whether the three R‐ISS groups could be divided into subgroups with different prognostic factors based on the detection of Circulating Plasma Cells (CPCs) at diagnosis, in this retrospective analysis, we evaluated 161 patients with MM treated at our centre between 2005 and 2017. In all, 57 patients (33·9%) were staged as R‐ISS III, 98 (58·3%) as R‐ISS II and six (3·6%) as R‐ISS I. CPCs were detected in 125 patients (74·4%), while in 43 patients (25·6%) no CPCs were seen. Our analysis revealed that Overall Survival (OS) and progression‐free survival (PFS) rates in R‐ISS II patients were higher in the subgroup without CPCs compared to the subgroup with ≥1 CPCs (OS: 44·7% vs. 16·3%, P = 0·0089; PFS: 27·8% vs. 8·1%, P = 0·0118). Our present findings suggest that the detection of CPCs at diagnosis may be used as a further prognostic biomarker to improve the risk stratification of patients with MM staged as R‐ISS II.Keywords
This publication has 27 references indexed in Scilit:
- Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patientsBlood Advances, 2017
- Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2017
- Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).Journal of Clinical Oncology, 2016
- Multiple Myeloma: Diagnosis and TreatmentMayo Clinic Proceedings, 2016
- Characteristics of exceptional responders to lenalidomide-based therapy in multiple myelomaBlood Cancer Journal, 2015
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- New Strategies in the Treatment of Multiple MyelomaClinical Cancer Research, 2013
- Multiple myeloma and the road to personalised medicineThe Lancet Oncology, 2011
- Multiple myelomaThe Lancet, 2009
- Plasma Cell Disorders: An Historical PerspectiveHematology-American Society Hematology Education Program, 2008